Journal of Pharmacogenomics & Pharmacoproteomics

Identifying effectiveness of the antitumor drugs and predicting the tumor response prior to therapy for personalizing cancer medicine

4^th International conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics

September 22-23, 2016 Phoenix, USA

Emad Y Moawad

Independent researcher graduated from faculty of Engineering Ain Shams University, Cairo, Egypt

Posters & Accepted Abstracts: J Pharmacogenomics Pharmacoproteomics

Abstract:

Identifying effectiveness of antitumor drugs enables to predict and optimize chemotherapies to personalize cancer medicine. The processes of tumor formation and cancer therapy are based mainly on the concept of doubling time-energy conversion (DT-EC) in which the conversion of doubling time into growth energy takes place. Monitoring the mechanical behavior of tumor response of the treated groups by that of the control groups with respect to the growth/or shrinkage constants along the corresponding periods determines the accumulated energy yield by the drug doses. Assessment of the efficient regimen for optimizing therapy would be based on achieving an accumulated DT-EC in the tumor cells by the regimen doses. The higher the energy yields by the same drug dose the more effectiveness of the applied regimen and vice versa. Then, efficiency of those applied regimens on different types of tumor models would be determined to assess the specifications of the personalized treatment schedule. The correlation and regression between the energy yield by the applied drug doses in optimal schedules (dependent variable) and value of those doses (independent variable) would be investigated to determine values of both variables that in perfect correlation. Thus, a dose-energy model with perfect fit for the studied drug would be constructed to administer the optimal dose in an efficient schedule. Accordingly, the therapeutic response of cancer to the studied drug could be predicted prior to therapy by identifying each of patient's histologic grade in vitro or in vivo and energy yield by the proposed (personalized) dose using the constructed dose-energy model of the antitumor drug.

Biography :

Email: emadmoawad@hotmail.com